Re and Tc Complexes with Pyrazolyl-containing Chelators: from Coordination Chemistry to Target-Specific Delivery of Radioactivity

João D. G. Correia, António Paulo and Isabel Santos*

Unidade de Ciências Químicas e Radiofarmacêuticas, Instituto Tecnológico e Nuclear, Estrada Nacional 10, 2686-953 Sacavém, Portugal

*isantos@itn.pt

Review Submitted to Current Radiopharmaceuticals

Keywords: Radiopharmaceuticals; Rhenium; Technetium-99m; Pyrazolyl-containing Ligands; Bifunctional Chelators; Biomolecules.
Abstract

The design of novel target-specific imaging agents based on $^{99m}$Tc requires a considerable development of its coordination chemistry. Among all oxidation states available for technetium (-I to VII), the V oxidation state has been the most extensively studied in radiopharmaceutical chemistry, and the majority of the $^{99m}$Tc-radiopharmaceuticals in clinical use contain the core [$^{99m}$Tc(O)]$^{3+}$. More recently, the remarkable features of the organometallic precursor $fac$-[M(CO)$_3$(H$_2$O)$_3$]$^+$ (M = Re, Tc), introduced by Alberto et al., brought renewed interest in the design of innovative low-oxidation $^{99m}$Tc-based radiopharmaceuticals. Owing to our interest on the design of innovative target-specific radioactive probes, we have been recently involved in the study of the chemistry of [M(O)]$^{3+}$ and $fac$-[M(CO)$_3$]$^+$ (M = Re, Tc) with chelators combining a pyrazolyl unit with aliphatic amines and/or carboxylic acids or thioethers. Such research efforts are reviewed herein, where we present an overview of the chemistry, radiochemistry and biological properties of Re and $^{99m}$Tc complexes anchored by those pyrazolyl-containing chelators with relevance in radiopharmaceutical research. The revised work focuses mainly on tricarbonyl M(I) complexes but M(V) oxocomplexes are also covered. This contribution intends to highlight the potential of pyrazolyl-containing chelators for the labeling of biologically active molecules with $^{99m}$Tc(I), being presented a variety of examples which include peptides, peptide nucleic acids, inhibitors/substrates of enzymes and DNA-binders.
Contents

1 - Introduction

2 – Neutral and Anionic Pyrazolyl-Containing Chelators
   2.1 – $^{99m}$Tc/Re Complexes with the $\left[M(O)\right]^{3+}$ Core
   2.2 – $^{99m}$Tc/Re Complexes with the $fac\left[M(CO)_3\right]^{+}$ Core
   2.3 - $^{99m}$Tc/Re Tricarbonyl Complexes Anchored by Bifunctional Chelators

3- Target-Specific Complexes
   3.1 – Introduction
   3.2 – Peptides
   3.3 – Peptide Nucleic Acids
   3.4. - Small Biomolecules
   3.5 – DNA-Binders

4 – Conclusions

5 – Acknowledgments

6 - References
Radiopharmaceuticals are drugs having in their composition a radionuclide and are used in nuclear medicine for diagnosis and therapy. The biodistribution of such compounds can be either determined by their chemical and physical properties – perfusion agents- or by their biological interactions - target-specific radiopharmaceuticals [1]. For the so called perfusion agents, the biological distribution is determined by blood flow, and they target high capacity systems, such as phagocytosis, hepatocyte clearance and glomerular filtration. The target-specific radiopharmaceuticals target low capacity systems, and their biodistribution is also determined by specific protein interactions, for example enzymatic- or receptor-binding interactions. The radiopharmaceuticals for diagnostic contain gamma- or positron-emitting radionuclides, being suitable for single photon emission tomography (SPECT) or positron emission tomography (PET), respectively [1,2]. The radiotracers in clinical use for diagnostic are predominantly metal-based complexes and the great majority of SPECT diagnostic radiopharmaceuticals currently available in nuclear medicine are either $^{99m}$Tc complexes or target-specific biomolecules labeled with $^{99m}$Tc or $^{111}$In [3]. The preferential use of $^{99m}$Tc, considered the workhorse of nuclear medicine, reflects the ideal nuclear properties of this radionuclide ($t_{1/2} = 6.02$ h; $E_{\gamma max} = 140$ keV), its low-cost and convenient availability from $^{99}$Mo/$^{99m}$Tc commercial generators. Another relevant feature of $^{99m}$Tc relates with its diverse and rich redox chemistry. However, the design of an imaging agent based on a radiometal, namely $^{99m}$Tc, requires a considerable development of its coordination chemistry. From all oxidation states available for technetium (from -I to VII), $^{99m}$Tc(V) has been the most extensively studied in radiopharmaceutical chemistry, and the cores $[^{99m}$Tc(O)]$^{3+}$, trans-$[^{99m}$Tc(O)$_2$]$^+$, $[^{99m}$Tc(N)]$^{2+}$ and $[^{99m}$Tc-HYNIC] the most exploited [3-9]. In general, low oxidation states have received little attention, despite the noteworthy success of the organometallic complex $[^{99m}$Tc(CNCH$_2$C(CH$_3$)$_2$OCH$_3$)$_6$$]^+$ (Sestamibi), which has been approved a few decades ago as a myocardium imaging agent [1]. Despite its clinical importance, Sestamibi was not a good precursor
to enter into the chemistry of Tc(I) due to its high stability. In this respect, the new organometallic fac-[M(CO)₃(H₂O)₃]⁺ (M = Re, Tc), introduced by Alberto et al, is an excellent precursor and has brought renewed interest in the design of radiopharmaceuticals based on low-oxidation states [10-13]. The easy preparation of fac-[M(CO)₃(H₂O)₃]⁺ (M=Re, Tc) directly from [MO₄]⁻, the chemical robustness of the fac-[M(CO)₃]⁺ core, and the lability of the three water molecules offered a great number of advantages for the design of innovative radiopharmaceuticals. Moreover, the small size of the fac-[M(CO)₃]⁺ core is expected to allow the labeling of low molecular weight biomolecules with retention of biological activity and specificity. However, the advances in the development of new Tc(I)-based radioactive probes for in vivo targeting of macromolecular structures still depend on the availability of chelating systems well-suited to be combined with different biomolecules [10-13]. In this sense, the chelates should distinguish themselves by high stability, small size, adaptable lipophilicity, absence of isomerism, and easy functionalization. Taking such prerequisites into account, a wide variety of bidentate and tridentate ligands have been evaluated as potential bifunctional chelators for labeling biologically interesting molecules with fac-[⁹⁹mTc(CO)₃] [10-13].

In the past few years, almost all oxidation states and cores of technetium have been reviewed, showing the role of Tc-coordination chemistry in the development of target-specific radiopharmaceuticals [3-13]. In these reviews, aspects such as the importance of the donor atom set on the thermodynamic stability and kinetic inertness of the metal complexes, the use of pharmacokinetic modifying linkers to improve target-to-background ratios and the effect of the bifunctional chelators on the affinity and specificity of the biomolecule for the target have also been discussed.

Owing to our interest on radiopharmaceutical chemistry, namely on the design of innovative target-specific radioactive probes, we have been studying the chemistry of [M(O)]³⁺ and fac-[M(CO)₃]⁺ (M = Re, Tc) with different chelators, which combine a pyrazolyl unit with aliphatic amines and/or carboxylic acids, phenols or thioethers, as shown in Scheme 1.
These pyrazolyl-based chelators present a wide range of adequate features for the development of new target-specific probes, namely high stability, water solubility, different coordination possibilities and easy functionalization. These set of features confer an high degree of versatility to the chelators, making them quite suitable for the stabilization of the units $[\text{M(O)}]^{3+}$ or $\text{fac-}[\text{M(CO)}_3]^+$ ($\text{M} = \text{Re, } ^{99m}\text{Tc}$), for conjugation to biomolecules of different nature, and for modulation of the pharmacokinetics of the final complexes. Herein, we will highlight relevant aspects of the chemistry of these pyrazolyl-containing chelators with the $[\text{M(O)}]^{3+}$ or $\text{fac-}[\text{M(CO)}_3]^+$ cores, as well as the suitability of the resulting building blocks for labeling biomolecules with $^{99m}\text{Tc}$. A special effort will be done to correlate the physico-chemical properties of the complexes with their biological properties and potential applications.
2. Neutral and Anionic Pyrazolyl-Containing Chelators

2.1. $^{99m}$Tc/Re complexes with the [M(O)]$^{3+}$ Core

The coordination capability of novel tetradentate chelators ($\text{L}^1\text{H}_3$) – ($\text{L}^3\text{H}_3$) of the N$_3$S type (Scheme 2), obtained by combining a pyrazolyl group with a mercaptoacetylglycine unit, was evaluated towards the [M(O)]$^{3+}$ (M = Re, $^{99m}$Tc) cores, aiming to assess their interest as potential bifunctional ligands [14]. It was expected that the aromatic pyrazolyl ring would confer some rigidity to the complexes with the consequent enhancement of their stability. The presence of a carboxylic acid group in the aromatic pyrazolyl ring in $\text{L}^3\text{H}_3$ should allow an easy coupling of biologically relevant molecules to the metal center.

![Scheme 2 - Tetradeative pyrazolyl-based N$_3$S-donor chelators](image)

Reaction of adequate Re(V) starting materials with the trityl-protected chelators $\text{L}^1\text{H}_3$ – $\text{L}^3\text{H}_3$ afforded almost quantitatively the neutral complexes [ReO(L)] ($L = L^1$ (1); $L^2$ (2); $L^3$, (3)) (Scheme 3). The coordination mode of the chelators was confirmed by NMR studies, including two-dimensional techniques ($^1$H/$^1$H COSY and $^1$H/$^{13}$C HSQC), and by X-ray diffraction analysis in the case of (2) (Fig. (1)). The metal center is five–coordinated, displaying a square pyramidal coordination geometry, as shown in Fig. (1).
Scheme 3 – Synthesis of M(V) (M = Re, $^{99m}$Tc) oxocomplexes with tetradentate pyrazolyl-based N$_3$S-donor chelators.

Fig. (1) – Molecular structure of the oxorhenium(V) complex (2) [14].
The synthesis of the congener \([^{99m}\text{Tc}\text{O}(L^1)]\) (1a) was achieved directly from \([^{99m}\text{Tc}\text{O}_4}^-\) in aqueous medium, in almost quantitative yield and with high specific activity and radiochemical purity (Scheme 3) [14]. Complex (1a) is moderately lipophilic (\(\log P_{o/w} = + 0.73 \pm 0.03\)), and displays a high in vitro stability in the presence of excess glutathione (10 – 20 mM). Biodistribution studies in mice have shown that (1a) undergoes rather slow blood clearance (3.5±0.8 % ID/g blood at 4 h p.i.) being excreted mainly through the hepatobiliary pathway with a relatively low excretion rate (22.6±7.0 % ID at 4 h p.i.). HPLC analysis of the blood and urine of mice injected with (1a) has shown that the intact complex is the unique radioactive species detected in the blood but revealed the presence of several metabolites in the urine. These biological data brought together pointed out that tetradeinate chelators of the \(\text{N}_3\text{S}\) type containing a pyrazolyl coordinating group are not very promising compounds to be explored as bifunctional ligands for the labeling of biomolecules using \(^{99m}\text{Tc(V)}\) oxocomplexes.

Mixed-ligand M(V) oxocomplexes of the so called “3+1” type, bearing tridentate/dinegative ligands and unidentate thiolate co-ligands, have been largely explored for labeling biomolecules, in alternative to the more classical approach based on oxocomplexes anchored by tetradeinate chelators [4,5]. However, with a few exceptions, these mixed-ligand complexes showed a pronounced tendency to undergo trans-chelation reactions in vivo as a result of available vacant coordination sites [4,5]. To circumvent this problem, several authors have focused on closed shell and hexa-coordinated “3+2” M(V) oxocomplexes. Most of the reported Re(V)/Tc(V) “3+2” oxocomplexes were obtained using a combination of tridentate/dinegative and bidentate/uninegative ligands containing \(P, N, S, O\) donor atoms. “3+2” Oxocomplexes anchored by tridentate/uninegative and bidentate/dinegative chelators are more scarce, being limited to a few examples of Re(V) compounds [4]. The suitability of the potentially tridentate/uninegative pyrazolyl-containing chelators 2-[2-(pyrazol-1-yl)ethylaminomethyl]phenol (L\(^4\)H) and 2-[2-(pyrazol-1-yl)ethylaminomethyl]phenol (L\(^5\)H) to stabilize “3+2” mixed-ligand complexes was evaluated, using the corresponding oxo-dichlorides as starting
materials and different bidentate co-ligands [15]. The compounds mer-[ReO(L⁴)Cl₂] (4) and fac-[ReO(L⁵)Cl₂] (5) were synthesized by reaction of the precursor (NBu₄)[ReOCl₄] with L⁴H and L⁵H, as shown in Scheme 4.

Scheme 4 – Oxorhenium(V) complexes (4) – (7) anchored by a pyrazole-containing Schiff base (L⁴) and respective amine (L⁵).

The reactivity of (5) towards potential bidentate/dianionic substrates has shown that the type of reaction observed is strongly dependent on the donor atom set of the incoming ligand. The presence of sulphur favors the displacement of the ancillary ligand (L⁵), preventing the formation of mixed-ligand complexes. By contrast, complex (5) reacted with (O,O)-bidentate substrates (1,2-ethanediol and oxalic
acid) providing the air and water-stable $\text{fac-}[\text{ReO}(L^5)(\text{OCH}_2\text{CH}_2\text{O})]$ (6) and $\text{fac-}[\text{ReO}(L^5)(\text{C}_2\text{O}_4)]$ (7). These complexes have been characterized by the common spectroscopic techniques (IR, $^1$H and $^{13}$C NMR), and also by X-ray diffraction analysis (Fig. (2)). In these complexes the metal is six-coordinated by the oxo-group and by the tridentate and bidentate chelators, displaying an octahedral coordination geometry, as depicted Fig. (2). These new (N,N,O)/(O,O) mixed-ligand oxorhenium(V) complexes did not emerge as promising tools to be further explored in radiopharmaceutical research due to the marked tendency of the respective ancillary ligand ($L^5$) to be replaced by thiol groups, which are ubiquitous in biological substrates like glutathione.

![Molecular structures of the oxorhenium(V) complexes (6) and (7) [15].](image)

**Fig. (2) – Molecular structures of the oxorhenium(V) complexes (6) and (7) [15].**

### 2.2 – $^{99m}$Tc/Re Complexes with the $\text{fac-}[\text{M(CO)}_3]^+$ Core

To access a general labeling protocol for biomolecules with $^{99m}$Tc(I), we have been exploring the pyrazolyl-containing compounds displayed in **Scheme 5** [16-19].
Scheme 5 – Pyrazolyl-containing ligands (L⁶) – (L¹¹).

The ligands (L⁶) – (L¹¹) stabilize the fac-[Re(CO)₃]⁺ moiety forming the well defined complexes (8) – (15) with a metal-to-ligand ratio 1:1 (Scheme 6).
The asymmetric ligands always coordinate as tridentate ((12) – (15)), while the coordination behavior of the symmetric ones, (L⁶) and (L⁷), depends on the nature of the donor atom set. Higher temperature forces the tridentate coordination of (L⁶) through the three nitrogen atoms (9), while in the case of (L⁷), the presence of the sulfur atom prevents the coordination of the second pyrazolyl ring (11). The coordination mode of this family of chelators was established by X-ray structural analysis (Fig. (3)) and by NMR spectroscopy.

Fig. (3) – Molecular structures of the tricarbonyl rhenium complexes (9) and (12) [16].

Reaction of the chelators (L⁶) and (L⁸) – (L¹¹) with the organometallic precursor fac-[⁹⁹ᵐ{Tc(CO)}₃(H₂O)₃]⁺ allowed the preparation of the analog cationic ⁹⁹ᵐ{Tc(I) complexes (9a) and (12a) – (15a) in high yield and high radiochemical purity [17-19]. The in vitro studies performed revealed that the pyrazole-diamine-containing complexes, (12a) and (14a), were prepared with higher specific activity, being more resistant to in vitro challenge with biologically relevant amino acid substrates like histidine or cysteine, when compared with the related cations anchored by pyrazole-dithioether chelators (N,S,S-donors). Biodistribution studies in mice indicated also that the complexes stabilized by ligands containing the pyrazolyl-diamine backbone are highly stable in vivo, presenting a fast rate of blood clearance and high rate of total radioactivity excretion, occurring primarily through the renal-urinary pathway.

We have also introduced and studied the novel potentially monoanionic chelators (L¹²H) (N,N,O-donor atom set) and (L¹³H) (N,S,O-donor atom set), which form neutral complexes of the type fac-
[M(CO)₃(k³-L)] (M = Re, ⁹⁹mTc; L = (L¹²), (L¹³)) by reaction with the appropriate precursor, under optimized reaction conditions (Scheme 7) [20,21].

![Chemical structure](image)

Scheme 7 – Synthesis of Re/⁹⁹mTc complexes of the type fac-[M(CO)₃(k³-L)] stabilized by anionic pyrazolyl-based chelators with N,X,O (X = N, (L¹²); S, (L¹³)) donor atom sets.

Complexes (16) and (17) have been fully characterized by the usual analytical techniques, including by X-ray crystallography. The complexes are neutral, and the metal is six-coordinated by three carbonyl ligands and by the monoanionic chelators, which act as tridentate through N,N,O (16) and N,S,O (17) donor atom sets as displayed in Fig. (4).
The NNO-donor (L₁²) appeared as the most promising monoanionic chelator to be further explored in the design of bifunctional chelating ligands for the labeling of small biomolecules, mainly due to the enhanced *in vitro* stability and more favourable biological profile of the corresponding $^{99m}$Tc(I) complex (16a).

All together, the *in vitro* and *in vivo* evaluation of $^{99m}$Tc(I) tricarbonyl complexes anchored by neutral (Scheme 6) or monoanionic pyrazolyl-containing chelators (Scheme 7) has shown that the replacement of amines by thioether coordinating groups led to complexes with lower specific activity, and less resistant to *in vitro* challenge with biologically relevant substrates, like histidine and cysteine. DFT (density functional theory) calculations have been performed in order to have a more rationale insight into the influence of the ligand donor atom set (N,N,O vs N,O,S; N,N,N vs N,N,S vs N,S,S) on the *in vitro* stability of neutral and cationic $^{99m}$Tc(I) complexes with tridentate pyrazolyl-containing ligands [21]. These studies have shown that the replacement of nitrogen by sulfur donor atoms led to slightly
less stable complexes ($\Delta E \sim 4\text{-}10$ kcal/mol). However, these differences are not significant enough to explain the lower \textit{in vitro} stability observed experimentally for the complexes with the ligands containing sulfur donor atoms, suggesting that such trend is not explained by thermodynamic factors and relies most likely on kinetic effects [21].

2.3 - $^{99m}$Tc/Re Tricarbonyl Complexes Anchored by Bifunctional Chelators

Owing to their highest specific activity, highest \textit{in vitro/in vivo} stability and more favourable pharmacokinetics, the Tc(I) complexes anchored by asymmetric pyrazolyl-diamine ligands (N,N,N-donors) and pyrazolyl-aminecarboxylic acid ligands (N,N,O-donors) have emerged as the best suited for the design of targeted-specific radiopharmaceuticals. An intrinsic advantage of these systems is their chemical versatility, which allows an easy control of the size and lipophilicity of the complexes, by varying the substituents at the aromatic ring, and different possibilities for biomolecules coupling, with retention of the coordination sphere. Such coupling can be done either at the pyrazolyl ring or at an aliphatic side chain attached to the ligand, through the use of an appropriate functional group (e.g. carboxylic acid).

Novel bifunctional chelating ligands, (L$^{14}$) – (L$^{18}$), analogs of the lead compounds (L$^{8}$) and (L$^{11}$), have been prepared using a multistep approach [18,19,22]. These chelators combine a N,N,N donor atom set for metal coordination and carboxylate pendant arms in the aromatic ring ((L$^{14}$) – (L$^{16}$)) or at the central amine of the ligand backbone ((L$^{17}$) and (L$^{18}$)) for coupling to biomolecules. The bifunctional chelators (L$^{14}$) – (L$^{18}$) reacted with adequate precursors to afford complexes of the type \textit{fac-} [Re(CO)$_3$(k$^3$-L)] (L = (L$^{14}$) – (L$^{18}$), Scheme 8), in which the chelators act as tridentate through the nitrogen atoms, similarly to what has been observed with the corresponding model complexes (12) and (14) (Scheme 6).
The $^{99m}$Tc analogs (18a) – (22a) were obtained in high yields (≥ 90%) with high radiochemical purity and specific activity, using ligand concentrations spanning from $10^{-4}$ to $10^{-5}$ M. All complexes are generically stable in vitro, namely against cysteine and histidine exchange reactions.

The biological properties of the cationic complexes (20a) and (22a) were assessed in CD1 mice at different time points, and compared with the pharmacokinetic profile of the analog model radioactive complexes (14a) and (12a), respectively [19, 23]. The resulting data showed that all complexes were rapidly cleared from blood and other main organs, primarily through the renal-urinary pathway with a small portion retained in the hepatobiliary tract. The main differences in the biodistribution of the different complexes were related to the clearance from tissues as well as to the rate of overall excretion. The compounds containing pendant free carboxylic acid groups (20a) and (22a) showed a faster clearance from the main organs and the total radioactivity excretion was relatively enhanced while the hepatic retention was reduced, as compared to the model complexes (14a) and (12a). This trend is however more pronounced in the case of (20a). As expected, the hepatic retention of the complexes is
also related with their lipo(hydro)philic character. In fact, (20a), which is the complex with the lowest hepatic retention, is also the less lipophilic (log $P_{o/w} = -2.35 \pm 0.01$) compared to the model complex (14a) (log $P_{o/w} = -0.93 \pm 0.01$).

In conclusion, the general features of the $^{99m}$Tc(I) complexes containing the bifunctional chelating ligands ($L^{16}$) and ($L^{18}$), such as in vitro stability, lipophilicity, and biological profile are very promising for labeling biologically active compounds.

Aiming to develop new strategies for the labeling of hydroxyl-containing biomolecules with the organometallic core $fac-[^{99m}$Tc(CO)$_3]^+$, we have also introduced a new chelator containing a pyrazolyl-amine backbone and a phosphonate monoester ($L^{19}H$) [24], which upon reaction with the corresponding organometallic precursor afforded the complexes $fac-[M(CO)_3(k^2-L^{19})]$ ($M = Re$, (23); $^{99m}$Tc, (23a)) (Scheme 9). The radiocomplex is stable both in vitro and in vivo, without any measurable decomposition or reoxidation. Biodistribution studies of (23a) in mice indicated a rapid blood clearance, as well as a relatively fast clearance from main organs, being excreted mainly through the hepatobiliary pathway.

![Scheme 9 – Preparation of the tricarbonyl complexes (23) and (23a).](image)

3- Target-Specific Complexes
3.1 Introduction

A great variety of biologically relevant molecules (“biomolecules”) based on monoclonal antibodies, peptides, non-peptidic small molecules, and oligonucleotide analogs, have been explored for target-specific delivery of radionuclides [3, 25-31]. These biomolecules must recognize cell surface markers or receptors over-expressed on malignant cells, intracellular metabolic pathways that are up-regulated in cancer, endogeneous analogs utilization or cellular processes closer to transcription. So far, among all the possible approaches for the design of target-specific radiopharmaceuticals, the use of bifunctional chelators for linking the radionuclide to the biomolecules has been the most successful. In the case of $^{99m}$Tc, we may refer $[^{99m}$Tc(O)(TRODAT)] and $^{99m}$Tc-depreotide (NeoTect®) as successful examples of such approach (Scheme 10) [1, 3, 32]. $[^{99m}$Tc(O)(TRODAT)] has been developed for imaging the dopamine transporter (DAT) for diagnosis of Parkinson’s disease, while $^{99m}$Tc-depreotide is a peptide-based compound for imaging somatostatin receptor-positive tumors in lungs.

![Scheme 10 – Target-specific radiopharmaceuticals.](image)

Taking into account the clinical relevance of different receptor families, intracellular metabolic pathways or endogenous gene expression, we have investigated the possibility of using bioactive
peptides, oligonucleotide analogs or low molecular weight compounds such as enzyme inhibitors/substrates (tyrosine kinase and inducible nitric oxide synthase) for target-specific delivery of $\text{fac-[}^{99m}\text{Tc(CO)}_3\text{]}^+$ [25-31]. To achieve this goal we have explored the bifunctional chelator approach using mainly $L^{18}$ (Scheme 8). Recently, we have also studied the conjugation of DNA-binding molecules to some of the above described pyrazolyl-diamine chelators, aiming to explore the possibility of using $^{99m}\text{Tc}$ for targeted therapy.

In the next sections, which are organized according to the nature of the targeting biomolecules, we will present our most relevant achievements in the target-specific delivery of $^{99m}\text{Tc(I)}$.

### 3.2 – Peptides

During the last decade, a significant research effort has been devoted to the finding of radiolabeled peptides suitable for the $\text{in vivo}$ detection, functional characterization or therapy of tumors [29-31]. Such research effort has been driven by the favorable features of peptides as carrier molecules that can recognize receptors overexpressed in tumor cells and involved in the different processes that underly tumor pathology, such as proliferation, angiogenesis or metastasis. So far, the most important achievements in this area have been obtained for somatostatin analogs (e.g. $^{111}\text{In-DTPA-octreotide - Octreoscan}^\text{®}$), which are clinically relevant for the management of relatively rare neuroendocrine malignancies [1,29]. At a pre-clinical stage, some progresses have also been reported for other classes of radiolabeled peptides, namely for analogs of bombesin (BBN) or $\alpha$-melanocyte stimulating hormone ($\alpha$-MSH), and for peptides containing the Arg-Gly-Asp amino acid sequence (RGD). However, further improvements are still needed for introducing this type of radiolabeled peptides into the clinical practice [30,31]. Aiming to contribute for the accomplishment of such general goal, we have explored the tricarbonyl technology and pyrazolyl-diamine chelators for $^{99m}\text{Tc}$-labelling of BBN analogs, $\alpha$-MSH analogs and cyclic RGD-based peptides, as reviewed herein.
Bombesin (BBN) is a 14 amino acid peptide with very high affinity for the gastrin-releasing peptide receptor (GRPr; BB2 or BBN receptor subtype 2). The GRPr is expressed on a variety of tumors including breast, prostate, pancreatic, and small-cell lung cancer [33-36]. Therefore, BBN or BBN derivatives have been utilized as targeting vectors for the design and development of GRPr-specific diagnostic or therapeutic radiopharmaceuticals [37-41]. Pyrazolyl-diamine BBN conjugates of the general structure \( L^{18\text{a}}-\text{X-BBN}[7-14]\text{NH}_2 \) (X = GGG, SSS, β-alanine), which present three different types of linkers between the peptide and the chelator, have been synthesized [19,42]. These conjugates allowed the preparation of the bioactive complexes \([^{99m}\text{Tc(CO)}_3(L^{18\text{a}}-\text{X-BBN}[7-14]\text{NH}_2)]^+ \) (X = GlyGlyGly, (24a); SerSerSer, (25a); β-alanine, (26a)) in high radiochemical yield (≥ 95%) by reaction with the precursor \([^{99m}\text{Tc(CO)}_3(\text{H}_2\text{O})]^+ \) (Scheme 11). All radioactive complexes showed remarkable \textit{in vitro} stability, as monitored by HPLC [19,42].

![Scheme 11](image_url)

\textbf{Scheme 11} – Radiosynthesis of the bioactive complexes \([^{99m}\text{Tc(CO)}_3(L^{18\text{a}}-\text{X-BBN}[7-14]\text{NH}_2)]^+ \) (X = GlyGlyGly, (24a); SerSerSer, (25a); β-alanine (26a)).

Competitive binding displacement assays in human prostate PC-3 tumor cells demonstrated specific binding affinity of the \( L^{18\text{a}}-\text{X-BBN}[7-14]\text{NH}_2 \) conjugates for the GRPr, with IC\(_{50}\) values of 0.2±0.02 nM (X = GlyGlyGly), 1.9 ± 0.10 nM (X = SerSerSer) and 0.7 ± 0.04 nM (X = β-alanine). \textit{In vitro} internalization and efflux studies in human prostate PC-3 cells showed an agonistic binding behavior.
for the radioconjugates (24a) - (26a). The highest uptake and residualization of radioactivity was observed for X = β-alanine, (26a), however, the exact mechanism for its increased retention is still unclear.

The pharmacokinetic profile and degree of tumor uptake for (24a) - (26a) was evaluated in SCID mice bearing xenografted human prostate PC-3 tumors. The radiopeptides showed an accumulation in tumor tissues of 1.76 ± 1.20% (24a) ID/g, 1.76 ± 0.79% ID/g (25a), and 1.08 ± 0.41% ID/g (26a) at 1 h pi. Blocking studies with “cold” BBN[1–14] reduced the accumulation of radioactivity in those tissues (~22 – 40% reduction, 1 h pi), demonstrating in vivo specificity of these analogues for GRPr-expressing cells.

Radiolabeled peptides containing the Arg-Gly-Asp amino acid consensus sequence (RGD) have also been extensively studied to develop site-directed targeting vectors for integrin receptors upregulated on tumor cells and neovasculature [43-46]. Integrin recognition of the canonical RGD sequence plays a pivotal role in many cell-cell and cell-extracellular matrix (ECM) interactions. The integrins of most interest in cancer imaging and therapy contain the αv subunit, particularly the αvβ3 and αvβ5 subtypes [47-49]. Aimed at introducing novel nuclear tools suitable to image angiogenesis and tumor formation in vivo, the cyclic RGD-based peptide conjugate cyclo-[Arg-Gly-Asp-D-Tyr-Lys(L18)] has been prepared. This conjugate reacted with [99mTc(CO)3(H2O)]+, giving [99mTc(CO)3cyclo-[Arg-Gly-Asp-D-Tyr-Lys(L18)]]+ (27a) in high yield (≥ 90%) and high specific activity (ca. 6 x 10^6 Ci/mol) (Scheme (12)) [50].
Scheme 12 – Radiosynthesis of $[^{99m}Tc(CO)_3cyclo-[Arg-Gly-Asp-D-Tyr-Lys(L^{18})]]^+$ (27a).

In vitro internalization and blocking assays in $\alpha_\text{v}\beta_3$ receptor-positive human M21 melanoma cancer cells showed that the radiopeptide (27a) has the ability to target the integrin receptor, with high specificity and selectivity. In vivo accumulation of radioactivity in mice bearing either $\alpha_\text{v}\beta_3$ receptor-positive or negative human melanoma tumors showed receptor specific uptake of the radiotracer with accumulations of $2.50 \pm 0.29$ ID/g and $0.71 \pm 0.08\%$ ID/g in $\alpha_\text{v}\beta_3$ integrin positive (M21) and negative (M21L) tumors at 1 h post-injection, respectively [50]. A comparative study with other cyclo-RGD peptides labeled with different $^{99m}$Tc-cores revealed that (27a) competed well with the best performing compound ($[^{99m}Tc]$EDDA/HYNIC-RGD) in terms of pharmacokinetic profile and receptor-mediated tumor uptake in mice bearing either $\alpha_\text{v}\beta_3$ receptor-positive or negative human melanoma tumors [51].

Most murine and human melanoma metastasis bear upregulated $\alpha$-melanocyte stimulating hormone ($\alpha$-MSH) receptors, namely the melanocortin type 1 receptor (MC1R). $\alpha$-MSH is the most potent naturally
occurring melanotropic peptide and the most active peptide of MC1R (Table 1) [52-54]. Therefore, in the last few years, a great deal of effort has been directed towards the development of radiolabeled analogs of the tridecapeptide α-MSH for diagnosis and treatment of melanoma [55-61]. Aiming to target the MC1R in vivo, we focused our attention on the labeling of α-MSH analogs containing the bifunctional chelator $L^{18}$ (Table 1, entries 3, 4 and 6) with the moiety $\text{fac-}[^{99m}\text{Tc(CO)}_3]^+$ [62-64].

**Table 1 – Structure of α-melanocyte-stimulating hormone and analogues**

<table>
<thead>
<tr>
<th>Entry</th>
<th>PEPTIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ac-Ser-Tyr-Ser- Met$^4$-Glu$^5$-His – Phe$^7$-Arg-Trp-Gly-Lys-Pro-Val-NH$_2$ (α-MSH)</td>
</tr>
<tr>
<td>2</td>
<td>Ac- Nle$^4$-c[Asp$^5$-His-DPhe$^7$-Arg-Trp-Lys]-NH$_2$ (MTII)</td>
</tr>
<tr>
<td>3</td>
<td>$L^{18}$-βAla$^3$-Nle$^4$-c[Asp$^5$-His-DPhe$^7$-Arg-Trp-Lys]-NH$_2$ (cyclic)</td>
</tr>
<tr>
<td>4</td>
<td>$L^{18}$-βAla$^3$-Nle$^4$-Asp$^5$-His-DPhe$^7$-Arg-Trp-Lys-NH$_2$ (linear)</td>
</tr>
<tr>
<td>5</td>
<td>Ac-Nle$^4$-Asp$^5$-His-DPhe$^7$-Arg-Trp-Gly-Lys-NH$_2$ (NAPamide)</td>
</tr>
<tr>
<td>6</td>
<td>Ac-Nle$^4$-Asp$^5$-His-DPhe$^7$-Arg-Trp-Gly-Lys($L^{18}$)-NH$_2$</td>
</tr>
</tbody>
</table>

The peptide conjugates (final concentration ~ 1-5 x 10$^{-5}$ M) reacted with the precursor $\text{fac-}[^{99m}\text{Tc(CO)}_3(\text{H}_2\text{O})]^+$, yielding (> 95%) stable radioactive complexes of the type $[^{99m}\text{Tc(CO)}_3-L]^+$ ($L = L^{18}$-βAla$^3$-Nle$^4$-c[Asp$^5$-His-DPhe$^7$-Arg-Trp-Lys]-NH$_2$, (28a); $L^{18}$-βAla$^3$-Nle$^4$-Asp$^5$-His-DPhe$^7$-Arg-Trp-Lys-NH$_2$, (29a); and Ac-Nle$^4$-Asp$^5$-His-DPhe$^7$-Arg-Trp-Gly-Lys($L^{18}$)-NH$_2$, (30a)).

The degree of internalization and cellular retention in B16F1 murine melanoma cells was used as a parameter for prediction of the tumor-targeting properties of the different radiopeptides. Higher levels of internalization were reached for the $^{99m}\text{Tc(CO)}_3$-labeled cyclic conjugate, compared with the linear analogs. Negligible amounts of radioactivity were internalized after 4 h for the linear radiopeptides ((29a): 1.6%; (30a): 5.4%), but remarkable internalization (50.5%, 4 h) was attained for the cyclic radioconjugate (28a). The latter internalization level is particularly high when compared with data previously reported for other radiolabeled α-MSH analogs, namely for the cyclic radiopeptide $^{99m}\text{Tc}$-CCMSH that showed a lower internalization (< 4%) under the same experimental conditions [55].
Biodistribution studies in melanoma-bearing C57BL6 mice have shown that the cyclic radioconjugate (28a) presents a significant MC1R-mediated tumor uptake (9.26 ± 0.83 and 11.31 ± 1.83% ID/g at 1 and 4 h postinjection, respectively), as confirmed by receptor-blocking studies with the potent (Nle⁴,DPhe⁷)-αMSH agonist. The linear ⁹⁹mTc(CO)₃-labeled peptide conjugates presented significantly lower tumor uptake values ((29a): 0.99 ± 0.08 % ID/g at 4 h postinjection; (30a): 4.24 ± 0.94 % ID/g, at 4 h postinjection). Despite the excellent tumor-targeting properties exhibited by the cyclic radiopeptide, improvement of its pharmacokinetic profile is needed to decrease kidney uptake and to increase the overall excretion. To achieve such goal the modification of the cyclic peptide conjugate is underway.

3.3 – Peptide Nucleic Acids

Peptide Nucleic acids (PNAs) are DNA analogs in which the sugar–phosphate backbone has been replaced by a pseudopeptide chain constituted by N-(2-aminoethyl)glycine [65-69]. PNAs are achiral, neutral, and stable over a wide range of pH, resistant to enzymatic degradation, and do not activate RNase H degradation of mRNA. They can also bind to complementary DNA/RNA, resulting in hybrid PNA/DNA or PNA/RNA duplexes which are thermodynamically more stable than the homoduplexes [65-69]. In the past few years, PNAs and their derivatives have been used as potential drugs, or as components for designing radioactive probes for *in vivo* imaging of endogenous gene expression trough the antisense strategy [70, 71]. The latter approach is directed to transcription of genes into messenger RNA (mRNA), using a complementary sequence of the target mRNA for imaging.

Aiming to explore the possibility of labeling clinically relevant PNA sequences with the organometallic core $\text{fac-}^{99m}\text{Tc(CO)₃}^+$ using the tridentate bifunctional ligand $\text{L}^{18}$, we synthesized and characterized the 16-mer peptide nucleic acid sequence H-AGAT CAT GCC CGG CAT-Lys-NH₂, complementary to the translation start region of the N-myc oncogene messenger RNA [72-77], and coupled it to $\text{L}^{18}$,
yielding the novel PNA-conjugate L\(^{18}\)-A GAT CAT GCC CGG CAT-Lys-NH\(_2\) [78-80]. The conjugate was labeled with technetium tricarbonyl, affording quantitatively \(\text{fac-}[^{99m}\text{Tc}](\text{CO})\text{L}^{18}\text{-A GAT CAT GCC CGG CAT-Lys-NH}_2\)]\(^{2+}\) (31a) with high radiochemical purity and high specific activity (Scheme 13). The identity of the radiocomplex was confirmed by comparing its reversed-phase high performance liquid chromatography profile with that of the rhenium analog, which has been prepared by using solid-phase synthesis techniques.

![Chemical Structure](image)

**Scheme 13** – Radiosynthesis of \(\text{fac-}[^{99m}\text{Tc}](\text{CO})\text{L}^{18}\text{-A GAT CAT GCC CGG CAT-Lys-NH}_2\)]\(^{2+}\) (31a).

UV melting experiments of H-AGAT CAT GCC CGG CAT-Lys-NH\(_2\) and \(\text{fac-}[\text{Re}(\text{CO})_3]\text{L}^{18}\text{-A GAT CAT GCC CGG CAT-Lys-NH}_2\)]\(^{2+}\), (31), with the complementary DNA sequence led to the formation of stable duplexes, indicating that the conjugation of the selected 16-mer peptide nucleic acid sequence to the bifunctional chelator and to the metal fragment \(\text{fac-}[\text{M}(\text{CO})_3]^+\) did not affect the recognition of the complementary sequence and the duplex stability.

Cell internalization and retention studies in N-myc expressing SH-SY5Y human neuroblastoma cells, revealed that (31a) internalizes (7% of the activity goes into the cells, after 4 h at 37 \(^\circ\)C) with a relatively high cellular retention (only 40% of internalized activity is released from the cells after 5 h). These values are in line with the reported higher permeability of neuronal cell lines to PNA, and with
the internalization of a rhodamine-conjugated PNA into neuroblastoma cells. The conjugation of a targeting specific vector to the radioconjugate is currently underway.

3.4. – Small Biomolecules

A set of $^{99m}$Tc(I) “bioactive” complexes, which comprise tridentate chelating units derived from ($L_{12}^H$) and ($L_{18}^H$) and pendant enzyme substrate/inhibitor (($L_{20}^H$) and ($L_{21}^H$) – ($L_{23}^H$)) or bone-seeking agents (($L_{24}^H$) – ($L_{26}^H$)) for \textit{in vivo} targeting of tumors and bone-associated diseases, respectively (Scheme 14).

\begin{center}
\begin{align*}
\text{M = Re (32), } &^{99m}\text{Tc (32a)} \\
\text{M = Re; } R = H (33) & \text{, NO}_2 (34), \text{Me (35)} \\
\text{M = } &^{99m}\text{Tc; } R = H (33a), \text{NO}_2 (34a), \text{Me (35a)} \\
\text{M = Re; } R = H (36), & \text{Et (37)} \\
\text{M = } &^{99m}\text{Tc; } R = H (36a), \text{Et (37a)} \\
\text{M = Re (38), } &^{99m}\text{Tc (38a)}
\end{align*}
\end{center}

\textbf{Scheme 14} – $^{99m}$Tc(I)/Re(I)-complexes bearing small biomolecules.
Tumour imaging of EGFR receptors with radioactive probes has been a field of intense research in the past few years, namely based on tyrosine kinase inhibitors such as quinazoline derivatives [81 - 90]. Searching for useful $^{99m}$Tc probes for early detection and staging of EGFR positive tumors, we have coupled the quinazoline pharmacophore (3-chloro-4-fluorophenyl)quinazoline-4,6-diamine to a tailor-made N$_2$O-tridentate chelator (L$_{20}$H) derived from L$_{12}$ (Scheme 7) [91-93]. The corresponding $^{99m}$Tc-complex (32a) was obtained in quantitative yield and with high radiochemical purity after optimization of the labeling conditions (Scheme 14).

In vitro studies confirmed that the corresponding Re complex (32a) still inhibits significantly the EGFR autophosphorylation and also inhibited A431 cell growth. Biodistribution studies with the $^{99m}$Tc complex in healthy and tumor-bearing mice are currently in progress to prove their usefulness as a tumor imaging agent.

Nitric oxide synthase (NOS) is the eukaryotic enzyme responsible for the endogenous catalytic oxidation of L-arginine to L-citrulline. This reaction generates nitric oxide (NO), a key signaling mammalian mediator in several physiological processes, such as vasodilation, thermoregulation, neurotransmission and host-defence [94, 95]. The enzyme presents three isoforms (neuronal NOS, Nnos; endothelial NOS, eNOS; and inducible NOS, iNOS). Insufficient NO bioavailability from eNOS and nNOS is associated with hypertension, impotence, atherosclerosis and cardiovascular disease, whereas overproduction of NO from nNOS and iNOS has been associated to Alzheimer’s and Parkinson’s diseases [96-98]. Overproduction of NO by iNOS has also been linked to multiple sclerosis, inflammation, rheumatoid arthritis, stroke and cancer [96-98]. The in vivo imaging of NOS expression using radiolabeled NOS substrates/inhibitors, holds great potential for providing an insight into the wide variety of diseases linked to abnormal NO production [99 - 101]. Thus, aiming to design radioactive compounds based on the core “$^{99m}$Tc(CO)$_3$” for probing nitric oxide synthase (iNOS) levels in vivo, we have synthesized the bioconjugates (L$_{21}$) – (L$_{23}$) derived from (L$_{18}$), which contain the
pyrazolyl-diamine chelating unit and pendant L-arginine analogues (substrates and inhibitors of NOS) [102]. Reaction of \((L^{21}) - (L^{23})\) with \(\text{fac-}[\text{M(CO)}_3]^+\) (\(\text{M} = \text{Re}, \ \text{\textsuperscript{99m}Tc}\)) gave bioorganometallic complexes of the type \(\text{fac-}[\text{M(CO)}_3(k^3-L)]\) \((L = (L^{21}), (33)/(33a); (L^{22}), (34)/(34a); (L^{23}), (35)/(35a))\) in good yield (Scheme 14) [102]. After \textit{in vitro} testing using the oxyhemoglobin NO capture assay, we concluded that the affinity of the inhibitor-containing conjugates to iNOS seems to be less affected upon metallation with rhenium than the substrate-containing conjugates. The rhenium complexes bearing guanidine-substituted analogues of L-arginine still present considerable inhibitory action \((34)\): \(K_i = 84 \ \mu\text{M}, \ R = \text{\textsuperscript{N}ω-nitro-L-arginine}; (35)\): \(K_i = 36 \ \mu\text{M}, \ R = \text{\textsuperscript{N}ω-monomethyl-L-arginine}\), being the first examples of organometallic complexes able to inhibit the iNOS (Scheme 14) [102].

Taken together, the enzymatic studies and the high stability shown by the radioactive complexes revealed that \textsuperscript{\textsuperscript{99m}Tc(CO)}\_3\textsuperscript{-labeled} L-arginine analogues, mainly NOS inhibitors, may hold great potential for monitoring increased levels of iNOS \textit{in vivo}. Biological assessment of these compounds in specific cell lines with localized iNOS expression (e.g. lipopolysaccharide-activated macrophages) and specific animal models is underway.

The \textsuperscript{\textsuperscript{99m}Tc}-labeled bisphosphonates \((\textsuperscript{\textsuperscript{99m}Tc-BP})\) routinely used for bone imaging \((\textsuperscript{\textsuperscript{99m}Tc-MDP, MDP} = \text{methylene phosphonate}, \ \text{and} \ \textsuperscript{\textsuperscript{99m}Tc-HMDP, HMDP} = \text{hydroxymethylene phosphonate})\) present several drawbacks, such as \textit{in vivo} instability, and relatively slow blood and soft-tissue clearance, delaying the start of the bone-scanning procedure in nuclear medicine centers [103 - 107]. From a chemical point of view, these \textsuperscript{\textsuperscript{99m}Tc-BP} radiopharmaceuticals do not present single, well-defined chemical species, but mixtures of short-chain and long-chain polymers, which may reduce the efficacy of the radiopharmaceutical [105]. Taken together, these disadvantages show that there is still space for the development of new bone-seeking radiotracers based on \textsuperscript{\textsuperscript{99m}Tc} with better chemical and biological properties. Therefore, aimed at developing new bone-seeking radiotracers based on the organometallic core \(\text{fac-}[\textsuperscript{\textsuperscript{99m}Tc(CO)}_3]^+\) with improved properties, we have prepared the new phosphonate-containing
conjugates \((L^{24})\) – \((L^{26})\) which bear the pyrazolyl-diamine chelating unit [22]. Reactions of these chelators with the precursor \([^{99m}\text{Tc}(\text{H}_2\text{O})_3(\text{CO})_3]^+\) yielded (> 95%) the single and well-defined complexes \((36a) – (38a)\) (Scheme 14). The corresponding Re surrogates ((36) – (38)), characterized by the usual analytical techniques, including X-ray diffraction analysis in the case of (37), allowed for the chemical identification of the radioactive conjugates.

Complexes \((36a) – (38a)\) revealed high stability both \textit{in vitro} (phosphate-buffered saline solution and human plasma) and \textit{in vivo}, without any measurable decomposition. Biodistribution studies of \((36a) – (38a)\) in mice indicated a fast rate of blood clearance and high rate of total radioactivity excretion, occurring primarily through the renal–urinary pathway in the case of \((38a)\). Despite presenting moderate bone uptake \((3.04 \pm 0.47\% \text{ injected dose per gram of organ, 4 h after injection})\), the high stability presented by the latter radiocomplex and its adequate \textit{in vivo} pharmacokinetics encourages the search for new ligands with the same chelating unit and different bisphosphonic acid pendant arms.

3.5 – DNA-Binders

\(^{99m}\text{Tc}\)-complexes may hold potential for targeted antitumor therapy since \(^{99m}\text{Tc}\) is also an Auger-electron emitting radiometal. However, due to the short range of Auger electrons, there is a need for preferential accumulation of the complexes into the nucleus of the tumor cells in order to elicit significant DNA damage, and consequently a therapeutic effect [108,109]. Therefore, the improvement of the therapeutic efficiency of \(^{99m}\text{Tc}\) requires the design of compounds having a better ability to target the nucleus. In this way, Alberto et al. have evaluated a \(^{99m}\text{Tc}(\text{I})\) tricarbonyl complex containing a pyrene intercalator and a NLS peptide, showing that this trifunctional complex can reach the nucleus of B16-F1 mouse melanoma cells, leading to much stronger radiotoxic effects compared with \([^{99m}\text{TcO}_4]^-\). The same group has observed that related tricarbonyl \(^{99m}\text{Tc}(\text{I})\) or Re(I) complexes bearing acridine
orange as a DNA-binding group can also target the nucleus of murine B16F1 cells without needing a carrier NLS sequence [110-112].

With the goal of developing $^{99m}$Tc radiopharmaceuticals for targeted radiotherapy, and taking advantage of the versatile nature of pyrazolyl-diamine chelators, we have introduced the novel ligands ($L^{27}$) and ($L^{28}$) that bear an anthracen-9-yl group as a DNA-binding fragment (Scheme 15) [113,114].

Scheme 15– Pyrazole-diamine chelators containing an anthracene cromophore and the corresponding organometallic complexes.
The evaluation of the coordination properties of \((L^{27})\) and \((L^{28})\) towards the \(fac-[M(CO)_{3}]^{+}\) moiety (\(M = {}^{99m}\text{Tc, Re}\)) led to the preparation of the organometallic complexes \((39)/(39a)\) and \((40)/(40a)\) (Scheme 15) \([113,114]\). The interaction of the ligands \((L^{27})\) and \((L^{28})\), and respective rhenium complexes with calf thymus (CT) DNA has been investigated with a variety of spectroscopic techniques (UV-visible, fluorescence, circular dichroism (CD) and linear dichroism (LD)). All of the evaluated compounds have shown a moderate affinity to CT DNA \((3.46 \times 10^{3} < K_b < 1.95 \times 10^{4})\), but the binding mode depends on the position of the chromophore in the framework of the pyrazolyl–diamine ligands. LD measurements have shown that \((L^{27})\) act as a DNA intercalator, but complex \((39)\) intercalates only partially. By contrast, the compounds with the anthracenyl group at the 4-position of the azolyl ring \((L^{28})\) and \((40)\) do not intercalate, and behave more like DNA groove binders. Independently of the mode of interaction with DNA, complexes \((39)\) and \((40)\) can reach the nucleus of murine B16-F1 cells, as demonstrated by fluorescence microscopy (Fig. (5)).
**Fig. (5)** - Fluorescence microscopy images of B16-F1 melanoma cells after 3 h of exposure to 80 µM of complexes (39) or (40) (cyan colour in left and right top panels, respectively) and compounds (L27) or (L28) (cyan colour in left and right bottom panels, respectively), followed by fixation and DNA staining with DRAQ5 (red color in all panels).

The intracellular distribution and radiotoxicity of the $^{99m}$Tc complexes, (39a) and (40a), were also evaluated using B16F1 murine melanoma cells. The radiotoxic effects depend very much on the position used to introduce the DNA binding group and are well correlated with the nuclear uptake of the compounds. Complex (40a), having the anthracenyl substituent at the 4-position of the pyrazolyl ring, rapidly entered the cells and accumulated inside the nucleus, exhibiting the highest radiotoxic effects. This compound induced an apoptotic cellular outcome, and its enhanced radiotoxic effects are certainly due to the Auger electrons emitted by the radiometal in close proximity to DNA. Hence, complex 40a appear as a promising platform to be further explored in the design of biospecific $^{99m}$Tc-complexes aiming at the further evaluation of the potential of $^{99m}$Tc in targeted radiotherapy.

**4 – Conclusions**

The tetradentate pyrazolyl-containing N3S-donor chelators did not emerge as promising compounds to be explored as bifunctional ligands for the labeling of biomolecules using $^{99m}$Tc(V) oxocomplexes, mainly due to the unfavorable pharmacokinetic profile shown by the radioactive model complexes. In addition, the new N,N,O/O,O mixed-ligand oxorhenium(V) complexes were also inadequate for radiopharmaceutical applications since were quite unstable in the presence of thiol-containing molecules. The tridentate asymmetric pyrazolyl-containing chelators with N,N,N (neutral) or N,N,O (monoanionic) donor atom sets described herein presented relevant features (e.g. high stability, water solubility, easy functionalization and coordination possibilities) for the design of innovative $^{99m}$Tc(I)-
based target-specific probes. Such versatility led to the preparation of a wide variety of well-defined cationic or neutral complexes of the type \( \text{fac-}[\text{M(CO)}_3(\text{k}^3-\text{L})]^{+/0} \) (M = Re, \( ^{99m}\text{Tc} \)) in high yield. The \( ^{99m}\text{Tc} \) model complexes, obtained in high radiochemical purity and high specific activity, were stable against cysteine and histidine exchange reactions and towards oxidation. These \textit{in vitro} results, together with the adequate biological profile, namely high stability \textit{in vivo} and fast clearance from blood and other main organs through the renal-urinary pathway, indicated that the chelators could be further explored in the design of bifunctional chelating ligands for the labeling of biomolecules. Our studies revealed that the functionalization of the model chelators through the central secondary amine, as well as through the pyrazolyl ring, did not change the coordination mode of the bifunctional chelators towards the tricarbonyl unit, and the biological properties of resulting complexes. Taking advantage of such properties, tumor-seeking peptides (bombesin and α-MSH analogs, and peptides containing the RGD sequence) and a peptide nucleic acid (PNA) have been conjugated to the chelators and labeled in high yield and high specific activity with the unit \( \text{fac-}[^{99m}\text{Tc(CO)}_3]^+ \). Despite exhibiting promising tumor-targeting properties, the pharmacokinetic profile of some of the labeled peptides has still to be further improved. Besides peptides, low molecular weight biomolecules such as quinazoline derivatives, bisphosphonates, L-arginine derivatives and DNA binders have also been labeled in high yield and high specific activity with retention of biological activity, as assessed using appropriate cell and animal models. In conclusion, the versatility of the pyrazolyl-containing chelators allowed the preparation of model \( ^{99m}\text{Tc} \) complexes with different physico-chemical and biological properties for the labeling of a wide range of relevant biomolecules, spanning from small lipophilic organic molecules, such as quinazoline derivatives, to tumor-seeking peptides for \textit{in-vivo} receptor targeting.

5 – Acknowledgements
We thank the Fundação para a Ciência e Tecnologia (PPCDT-POCI/SAU-FCF/58855/2004; XXXXXX) and Mallinkrodt-Tyco Inc. (MM) for financial support. MM is also acknowledged for providing the IsoLink® kits. The authors thank Carolina Moura for Molecular Structures drawing.
6 – References


